

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/085766 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/5377 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/052002

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/545,133 20 October 2023 (20.10.2023) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];
Route 206 and Province Line Road, Princeton, New Jersey
08543 (US).

(72) Inventors: **WANG, Nan**; c/o J-Star Research, Inc., 6
Cedarbrook, Cranbury, New Jersey 08512 (US). **SHAH,
Harsh**; c/o J-Star Research, Inc., 6 Cedarbrook, Cranbury,
New Jersey 08512 (US). **KUANG, Shanming**; c/o J-Star
Research, Inc., 6 Cedarbrook, Cranbury, New Jersey 08512
(US). **O'CONNOR, James**; c/o J-Star Research, Inc., 6
Cedarbrook, Cranbury, New Jersey 08512 (US). **CHAD-
HA, Aastha**; c/o Bristol-Myers Squibb Company, Route
206 and Province Line Road, Princeton, New Jersey 08543
(US). **SCATTOLIN, Thomas**; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US). **CHEN, Cheng**; c/o Bristol-M-
yers Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US).

(74) Agent: **ISSAC, Roy** et al.; Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, New Jersey
08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))



WO 2025/085766 A1

(54) Title: CRYSTALLINE FORMS OF FUMARATE SALT OF MRTX0902

(57) Abstract: The present invention relates to fumarate crystalline forms of MRTX0902 ((R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile), pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.